Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array Reports Preliminary Results From Phase 2 Trial Of ARRY-162
Array BioPharma (Array) has reported its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week phase 2 clinical trial with
Array BioPharma (Array) has reported its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week phase 2 clinical trial with
Sinovac Biotech (Sinovac) has reported that the State Food and Drug Administration (SFDA) has approved the registration application for PANFLU.1, Sinovac’s H1N1 vaccine, and has issued Sinovac a
Upp Technology has reported that it has added significant enhancements to its irms|EM (Emergency Management) software. The new irms|EM product enhancements streamline the order fulfillment and distribution process
Shire has received approval from the FDA for Intuniv (guanfacine) extended release tablets for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17
StemCells has published its preclinical data demonstrating that transplantation of its proprietary, purified human neural stem cells delays the loss of motor function in a mouse model of
China Aoxing has submitted a new drug application (NDA) to the China State Food and Drug Administration (SFDA) for its Codeine Phosphate, a compound oral solution for the
Coughlin Stoia Geller Rudman & Robbins (Coughlin Stoia) has filed a class action lawsuit on behalf of an institutional investor in the US District Court for the District
Thermo Fisher Scientific has signed an agreement to acquire BRAHMS for approximately $470m. The transaction is expected to be accretive to earnings per share in 2010. The transaction,
Target has reported that flu vaccinations are now available at all six Target Clinic locations in Maryland. Reportedly, the vaccines offered will include flu vaccinations (ages 18 months
Dainippon Sumitomo Pharma(DSP) and Sepracor have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of